Mark Knafl

428 total citations
13 papers, 22 citations indexed

About

Mark Knafl is a scholar working on Oncology, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Mark Knafl has authored 13 papers receiving a total of 22 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Surgery and 3 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Mark Knafl's work include Colorectal and Anal Carcinomas (3 papers), Radiomics and Machine Learning in Medical Imaging (2 papers) and Multiple Myeloma Research and Treatments (2 papers). Mark Knafl is often cited by papers focused on Colorectal and Anal Carcinomas (3 papers), Radiomics and Machine Learning in Medical Imaging (2 papers) and Multiple Myeloma Research and Treatments (2 papers). Mark Knafl collaborates with scholars based in United States, Italy and Denmark. Mark Knafl's co-authors include Scott E. Woodman, John Paul Shen, Abdelrahman Yousef, Rebecca A. Harrison, Ashish Damania, Xingzhi Song, Anne S. Tsao, Savitri Krishnamurthy, Vinod Ravi and Dan Zhao and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Mark Knafl

12 papers receiving 22 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark Knafl United States 3 9 8 7 4 4 13 22
Eid Hanna Hungary 2 10 1.1× 10 1.3× 5 0.7× 8 2.0× 5 1.3× 6 25
Patrick Tomboc United States 3 8 0.9× 5 0.6× 8 1.1× 7 1.8× 4 1.0× 7 24
E. Fonseca Spain 3 9 1.0× 6 0.8× 13 1.9× 4 1.0× 2 0.5× 15 23
Yoshiyasu Umeda Japan 2 7 0.8× 12 1.5× 7 1.0× 3 0.8× 3 0.8× 4 17
Dilip Harindran Vallathol India 3 16 1.8× 6 0.8× 7 1.0× 2 0.5× 7 1.8× 11 27
Alma Blázquez‐Martín Spain 3 10 1.1× 12 1.5× 7 1.0× 5 1.3× 7 24
Tessa Fulton‐Lieuw United Kingdom 5 12 1.3× 9 1.1× 6 0.9× 6 1.5× 11 37
Wenbin Yue China 3 7 0.8× 6 0.8× 6 0.9× 3 0.8× 3 17
Abhishek Doshi United States 3 19 2.1× 5 0.6× 15 2.1× 7 1.8× 3 0.8× 4 32
Hanna Cholewa Spain 3 7 0.8× 16 2.0× 7 1.0× 3 0.8× 2 0.5× 17 28

Countries citing papers authored by Mark Knafl

Since Specialization
Citations

This map shows the geographic impact of Mark Knafl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Knafl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Knafl more than expected).

Fields of papers citing papers by Mark Knafl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Knafl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Knafl. The network helps show where Mark Knafl may publish in the future.

Co-authorship network of co-authors of Mark Knafl

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Knafl. A scholar is included among the top collaborators of Mark Knafl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Knafl. Mark Knafl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

13 of 13 papers shown
1.
Morris, Van K., Suyu Liu, Kangyu Lin, et al.. (2025). Phase II Trial of Atezolizumab and Bevacizumab for Treatment of HPV-Positive Unresectable or Metastatic Squamous Cell Carcinoma of the Anal Canal. Clinical Cancer Research. 31(9). 1657–1666. 1 indexed citations
2.
Hornstein, Nicholas J., Mohammad A. Zeineddine, Andrew J. Pellatt, et al.. (2024). Efficacy and Safety of Atezolizumab and Bevacizumab in Appendiceal Adenocarcinoma. Cancer Research Communications. 4(5). 1363–1368. 3 indexed citations
3.
Bhutiani, Neal, Abdelrahman Yousef, Mohammad A. Zeineddine, et al.. (2024). Automated, High-Throughput Platform to Generate a High-Reliability, Comprehensive Rectal Cancer Database. JCO Clinical Cancer Informatics. 8(8). e2300219–e2300219. 4 indexed citations
4.
Hurd, Mark W., Abdelrahman Yousef, Rebecca A. Snyder, et al.. (2024). Frequency and oncologic outcomes of KRAS mutations in circulating tumor DNA of patients with pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 42(3_suppl). 636–636. 2 indexed citations
5.
Morris, Van K., Haifeng Zhu, Xiaoling Li, et al.. (2023). P-230 Biomarkers associated with survival benefit to atezolizumab and bevacizumab for treatment of metastatic anal cancer. Annals of Oncology. 34. S97–S97. 1 indexed citations
6.
7.
Yang, Joanna C., Jillian R. Gunther, Carla Hajj, et al.. (2023). Efficacy and toxicity of hypofractionated radiation therapy for patients with hematologic malignancies: update on a COVID era ILROG collaborative report. Hematological Oncology. 41(S2). 609–610. 1 indexed citations
8.
Wang, Xiaoping, Li Zhao, Takashi Semba, et al.. (2023). Abstract 1395: Genomic and transcriptomic analyses identify distinct features of triple-negative inflammatory breast cancer. Cancer Research. 83(7_Supplement). 1395–1395.
9.
Qazilbash, Muzaffar H., Penny Fang, Susan Wu, et al.. (2022). Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma. Transplantation and Cellular Therapy. 29(1). 37.e1–37.e7. 2 indexed citations
10.
Long, James P., Mark Knafl, Sairah Ahmed, et al.. (2022). Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections. Blood. 140(Supplement 1). 10907–10908. 1 indexed citations
11.
Weathers, Shiao‐Pei, Haifeng Zhu, Mark Knafl, et al.. (2022). Baseline tumor genomic and gut microbiota association with clinical outcomes in newly diagnosed glioblastoma (GBM) treated with atezolizumab in combination with temozolomide (TMZ) and radiation.. Journal of Clinical Oncology. 40(16_suppl). 2006–2006. 3 indexed citations
12.
Overman, Michael J., Mark Knafl, Anaís Malpica, et al.. (2021). Comprehensive genomic profiling of malignant peritoneal mesothelioma (MPeM) reveals key genomic alterations (GAs) distinct from malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology. 39(15_suppl). 8557–8557. 1 indexed citations
13.
Qazilbash, Muzaffar H., Penny Fang, Susan Wu, et al.. (2021). Radiation Therapy can be Safely Incorporated Into Pre-Transplant Treatment Regimens for Patients With Multiple Myeloma. International Journal of Radiation Oncology*Biology*Physics. 111(3). S81–S81. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eid Hanna Breakdown of academic impact, for papers by Patrick Tomboc Breakdown of academic impact, for papers by E. Fonseca Breakdown of academic impact, for papers by Yoshiyasu Umeda Breakdown of academic impact, for papers by Dilip Harindran Vallathol Breakdown of academic impact, for papers by Alma Blázquez‐Martín Breakdown of academic impact, for papers by Tessa Fulton‐Lieuw Breakdown of academic impact, for papers by Wenbin Yue Breakdown of academic impact, for papers by Abhishek Doshi Breakdown of academic impact, for papers by Hanna Cholewa
Rankless by CCL
2026